1. ,Zhengzhou,China
2. ,Zhengzhou,China
扫 描 看 全 文
The effect of 3% diquafosol on the improvement of ocular surface post cataract surgery: A meta-analysis for time of intervention[J]. 眼科实践与研究新进展, 2022,2(3):100063.
Yuhang Zhang, Ying Qi, Xiaohang Xie, et al. The effect of 3% diquafosol on the improvement of ocular surface post cataract surgery: A meta-analysis for time of intervention[J]. AOPR, 2022,2(3):100063.
The effect of 3% diquafosol on the improvement of ocular surface post cataract surgery: A meta-analysis for time of intervention[J]. 眼科实践与研究新进展, 2022,2(3):100063. DOI: 10.1016/j.aopr.2022.100063.
Yuhang Zhang, Ying Qi, Xiaohang Xie, et al. The effect of 3% diquafosol on the improvement of ocular surface post cataract surgery: A meta-analysis for time of intervention[J]. AOPR, 2022,2(3):100063. DOI: 10.1016/j.aopr.2022.100063.
Purpose,The effect of interventional time for 3% Diquafosol reatment in post-cataract surgery has not been well established. A meta-analysis was performed to evaluate the improvement of ocular surface condition in post-cataract surgery patients who received 3% DQS for various treatment durations.,Methods,Studies were performed based on 5 databases: PubMed, Cochrane Library, Web of Science, Embase, and China National Knowledge Infrastructure. Data on changes in Schirmer’s test, tear breakup time (TBUT), corneal staining score, and OSDI score were collected for meta-analysis.,Results,A total of 621 affected eyes from 9 independent clinical studies were included. 6 studies conducted Schirmer's test after the application of 3% DQS. Meta-analysis showed that the difference between 3% DQS and control groups was not statistically significant for short-term application (less than or equal to 1 month) (WMD = 0.14,P, = 0.27, 95% CI:-0.11 to 0.39), but was statistically different for long-term application (longer than or equal to 3 months) (WMD = 0.76,P, = 0.03, 95% CI:0.08 to 1.45). For the corneal fluorescence staining score, the data from 6 studies indicated that the improvement was statistically significant for short-term application (WMD = -0.40,P,<,0.00001, 95% CI:-0.72 to -0.08) and but not long-term application (WMD = -0.21,P, = 0.26, 95% CI:-0.57 to 0.15). For TBUT, the data from 9 studies indicated that both short-term and long-term application showed significant improvement (WMD = 1.70,P,<,0.00001, 95% CI:1.38 to 2.03; WMD = 1.52,P,<,0.00001, 95% CI:1.09 to 1.95). Similar results were observed in data from 5 studies with OSDI scores, where both short-term and long-term application showed statistically significant improvements (WMD = -5.41,P,<,0.00001, 95% CI: -7.02 to -3.81; WMD = -6.10,P,<,0.00001, 95% CI:-8.52 to -3.67).,Conclusions,The application of 3% DQS in post-operative cataract patients has a positive effect on improving the ocular surface conditions. Short-term application resulted in lower corneal staining scores, prolonged TBUT, and improved OSDI scores. Long-term application improved Schirmer's test results, TBUT, and subjective symptoms.,Key messages,The updated article suggests that 3% Diquafosol is less effective in the short term after cataract surgery, and that application over three months can improve the patient's ocular surface condition.
Purpose,The effect of interventional time for 3% Diquafosol reatment in post-cataract surgery has not been well established. A meta-analysis was performed to evaluate the improvement of ocular surface condition in post-cataract surgery patients who received 3% DQS for various treatment durations.,Methods,Studies were performed based on 5 databases: PubMed, Cochrane Library, Web of Science, Embase, and China National Knowledge Infrastructure. Data on changes in Schirmer’s test, tear breakup time (TBUT), corneal staining score, and OSDI score were collected for meta-analysis.,Results,A total of 621 affected eyes from 9 independent clinical studies were included. 6 studies conducted Schirmer's test after the application of 3% DQS. Meta-analysis showed that the difference between 3% DQS and control groups was not statistically significant for short-term application (less than or equal to 1 month) (WMD = 0.14,P, = 0.27, 95% CI:-0.11 to 0.39), but was statistically different for long-term application (longer than or equal to 3 months) (WMD = 0.76,P, = 0.03, 95% CI:0.08 to 1.45). For the corneal fluorescence staining score, the data from 6 studies indicated that the improvement was statistically significant for short-term application (WMD = -0.40,P,<,0.00001, 95% CI:-0.72 to -0.08) and but not long-term application (WMD = -0.21,P, = 0.26, 95% CI:-0.57 to 0.15). For TBUT, the data from 9 studies indicated that both short-term and long-term application showed significant improvement (WMD = 1.70,P,<,0.00001, 95% CI:1.38 to 2.03; WMD = 1.52,P,<,0.00001, 95% CI:1.09 to 1.95). Similar results were observed in data from 5 studies with OSDI scores, where both short-term and long-term application showed statistically significant improvements (WMD = -5.41,P,<,0.00001, 95% CI: -7.02 to -3.81; WMD = -6.10,P,<,0.00001, 95% CI:-8.52 to -3.67).,Conclusions,The application of 3% DQS in post-operative cataract patients has a positive effect on improving the ocular surface conditions. Short-term application resulted in lower corneal staining scores, prolonged TBUT, and improved OSDI scores. Long-term application improved Schirmer's test results, TBUT, and subjective symptoms.,Key messages,The updated article suggests that 3% Diquafosol is less effective in the short term after cataract surgery, and that application over three months can improve the patient's ocular surface condition.
DiquafosolCataract surgeryOcular surfaceMeta-analysis
1 Y.K. Cho, M.S. KimDry eye after cataract surgery and associated intraoperative risk factors Kor J Ophthalmol, 23 (2) (2009), pp. 65-73, 10.3341/kjo.2009.23.2.65
2 X.M. Li, L. Hu, J. Hu, et al.Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery Cornea, 26 (9 Suppl 1) (2007), pp. S16-S20, 10.1097/ICO.0b013e31812f67ca
3 K. Kato, K. Miyake, N. Kondo, et al.Conjunctival goblet cell density following cataract surgery with diclofenac versus diclofenac and rebamipide: a randomized trial Am J Ophthalmol, 181 (2017), pp. 26-36, 10.1016/j.ajo.2017.06.016
4 R. Michael, A. WegenerEstimation of safe exposure time from an ophthalmic operating microscope with regard to ultraviolet radiation and blue-light hazards to the eye J Opt Soc Am Opt Image Sci Vis, 21 (8) (2004), pp. 1388-1392, 10.1364/josaa.21.001388
5 G.M. KeatingDiquafosol ophthalmic solution 3 %: a review of its use in dry eye Drugs, 75 (8) (2015), pp. 911-922, 10.1007/s40265-015-0409-7
6 D. Wu, W.Q. Chen, R. Li, et al.Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: a systematic review of randomized clinical trials Cornea, 34 (6) (2015), pp. 644-650, 10.1097/ico.0000000000000429
7 S. KohClinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes Clin Ophthalmol, 9 (2015), pp. 865-872, 10.2147/opth.S69486
8 X. Zhao, S. Xia, Y. ChenComparison of the efficacy between topical diquafosol and artificial tears in the treatment of dry eye following cataract surgery: a meta-analysis of randomized controlled trials Medicine (Baltim), 96 (39) (2017), Article e8174, 10.1097/MD.0000000000008174
9 D.H. Park, J.K. Chung, D.R. Seo, et al.Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery: a randomized controlled trial Am J Ophthalmol, 163 (2016), pp. 122-131 e2, 10.1016/j.ajo.2015.12.002
10 H. Lee, S.M. Kim, S. Choi, et al.Effect of diquafosol three per cent ophthalmic solution on tear film and corneal aberrations after cataract surgery Clin Exp Optom, 100 (6) (2017), pp. 590-594, 10.1111/cxo.12521
11 L. Cui, Y. Li, H.S. Lee, et al.Effect of diquafosol tetrasodium 3% on the conjunctival surface and clinical findings after cataract surgery in patients with dry eye Int Ophthalmol, 38 (5) (2018), pp. 2021-2030, 10.1007/s10792-017-0693-1
12 J. Baek, S.H. Doh, S.K. ChungThe effect of topical diquafosol tetrasodium 3% on dry eye after cataract surgery Curr Eye Res, 41 (10) (2016), pp. 1281-1285, 10.3109/02713683.2015.1122813
13 K. Miyake, N. YokoiInfluence on ocular surface after cataract surgery and effect of topical diquafosol on postoperative dry eye: a multicenter prospective randomized study Clin Ophthalmol, 11 (2017), pp. 529-540, 10.2147/opth.S129178
14 S. Kim, J. Shin, J.E. LeeA randomised, prospective study of the effects of 3% diquafosol on ocular surface following cataract surgery Sci Rep, 11 (1) (2021), p. 9124, 10.1038/s41598-021-88589-7
15 Y. Inoue, S. OchiEffects of 3% diquafosol sodium ophthalmic solution on higher-order aberrations in patients diagnosed with dry eye after cataract surgery Clin Ophthalmol, 11 (2017), pp. 87-93, 10.2147/opth.S122542
16 I. Jun, S. Choi, G.Y. Lee, et al.Effects of preservative-free 3% diquafosol in patients with pre-existing dry eye disease after cataract surgery: a randomized clinical trial Sci Rep, 9 (1) (2019), p. 12659, 10.1038/s41598-019-49159-0
17 L. Yang, Y. Jianguo, Q. Shixin, et al.Study on the effect of diquafosol sodium ophthalmic solution combined with sodium hyaluronate eye drops in the treatment of xerophthalmia after cataract surgery J China Prescr Drugs, 7 (18) (2020), pp. 103-104, 10.3969/j.issn.1671-945X.2020.07.055
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构